TCIM
RNTX

TIAA CREF Investment Management’s Rein Therapeutics RNTX Stock Holding History

TIAA CREF Investment Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-322
Closed -$68K – 3071
2017
Q4 		$68K Buy
322
+279
+649% +$66.9K ﹤0.01% 3054
2017
Q3 		$11K Buy
+43
New +$10.8K ﹤0.01% 3086

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TIAA CREF Investment Management's RNTX Position: Q1 2018 in Review

TIAA CREF Investment Management sold out of Rein Therapeutics (RNTX) in Q1 2018, closing a stake of 322 shares — an estimated $68K sold.

TIAA CREF Investment Management first reported a position in RNTX in Q3 2017 and held it in 2 quarters. The position peaked at $68K in Q4 2017. 27 funds tracked by Wall St. Rank hold RNTX as of Q1 2018.

  • TIAA CREF Investment Management reported no remaining Rein Therapeutics position as of Q1 2018 after selling out during the quarter.
  • TIAA CREF Investment Management sold 322 Rein Therapeutics shares in Q1 2018, an estimated $68K.
  • TIAA CREF Investment Management first reported a position in Rein Therapeutics in Q3 2017 and held it in 2 quarters.
  • TIAA CREF Investment Management's Rein Therapeutics position peaked at $68K in Q4 2017.
  • 27 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2018.

Based on TIAA CREF Investment Management's 13F filing for Q1 2018, filed 14 May 2018.